U.S. Markets closed

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.57-0.02 (-1.26%)
At close: 4:00PM EDT
People also watch
ARQLCERSAGENARRYCYTR
  • D
    David
    David
    $1.85 Private placement = $1.60 for long investors who were in prior to the add on

    No over yet, $1.42 looks to be the next actual support level, camel boy has no timing skills or ability to run a biotech company!
  • M
    Mario
    Mario
    1.85. It is official (SEC Filings).
  • D
    Davebiotech
    Davebiotech
    This mgt team can't seem to get it right. Almost done exiting this POS co.
  • A
    Anna
    Anna
    The trading setup for CRIS looks very enticing. the other week awe-some_sto-cks alerted this company i think. google them .
  • S
    Savannah
    Savannah
    Very difficult to see CRIS not making a big run north. Im not sure about you guys but awe.som_sto-cks has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • F
    Faith
    Faith

    My guess is that CRIS is due for a pullback in the short-run. https://activepennystocks1.blogspot.com just allerted a new stock - it beats having to dig online yourself for new stock ideas.

    Penny Stock
    activepennystocks1.blogspot.com
  • P
    Peter
    Peter
    Hate to be a debby downer but this stock is head to $1. No revenue in sight as 907 has been set back and Curis must raise money to stay afloat. Since it obtained approval of Erivedge back in January 2012 the stock has been a disaster.
  • P
    Peter
    Peter
    Public Offering Price
    $ 1.85 $ 37,000,000
    Underwriting Discounts and Commissions (1)
    $ 0.07 $ 1,400,000
    Proceeds to Curis before expenses
    $ 1.78 $ 35,600,000

    (1) The underwriter will be reimbursed for certain expenses in this offering. See “Underwriting” for details.
    Delivery of the shares of common stock is expected to be made on or about September 18, 2017. We have granted the underwriter an option for a period of 30 days to purchase up to 3,000,000 additional shares of our common stock. If the underwriter exercises this option in full, the total underwriting discounts and commissions payable by us will be $1,610,000 and the total proceeds to us, before expenses, will be $40,940,000.
  • D
    David
    David
    No doubt private investors got a 20% discount to the $2.02 close yesterday. Once the POS CEO Ali and the rest of the POS BOD fill in the blanks, (prospective) we will watch the share price sell off another .20 tomorrow

    Add on went off at $1.60, Ali and the BOD efinsuck
  • D
    David
    David
    $1.60 ....Camel boy sold us out!
  • P
    Peter
    Peter
    Can we learn anything at CITC in earlyj November about clinical profile of CA-170 that we did not learn from the poster presentation at ESMO? What is the next catalyst? I wonder who Baird got to buy the 20,000,000 share offering.
  • K
    Kenneth
    Kenneth
    Results sound very promising.
  • D
    David
    David
    Before Ali became CEO, he was previously appointed cleaner of the camel dung

    Then the camel bag holder

    Then on to CEO

    This entire management team from the BOD to operations including the CEO must go immediately before they destroy share holder value in its entirety!
  • T
    T
    T
    share price rose nearly 54% from its August low to Friday's high (80 cents, bottom to top). Close today down 27 cents from Friday's high. whatever the disappointment that there wasn't some kind of blowout positive news today, it seems likely that today's retreat involved "sell the news" and it wasn't extreme relative to the runup.
  • P
    Peter
    Peter
    reminds me of ph 1 preliminary results of 907, street deemed them underwhelming; only Curis can manage to disappoint on a day the stock market is soaring; as usual results not strong enough to trigger a major upswing and they need to raise some capital asap. Any postiive analysis would be welcome.
  • j
    john
    john
    1st in class................POS
  • D
    David
    David
    Thanks
  • D
    David
    David
    You suck Ali, step down and let someone that know anything Ron the company

    Go back to the camel farm
  • s
    shalom
    shalom
    ESMO DATA
    Ali said at the Baird conference that we are getting ca170 data on monday. also said they will provide an update at SITC in Nov. I cant tell from his tone in the baird conference but seems like we have activity. listen to audio at about 24:45 he says they do chew away at tumor. good luck next week
  • K
    Ken
    Ken
    Business wire reported phase 2 trials performed in US, SOUTH KOREA, and soon INDIA. Results vary based amounts of medicine used and cancer conditions of patients.